Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-03-02
Based on 664 first isolates · URO · Cystitis (lower UTI) · 2024-03-03 → 2025-03-02
Urology
Per-organism detail: URO urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 83 % (80 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (6 %), Klebsiella pneumoniae (5 %), Pseudomonas aeruginosa (5 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
84 %
82 %
n = 38
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
83 %
84 %
n = 38
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
76 %
n = 38
ceftriaxone CRO
trend · Escherichia coli
76 %
68 %
n = 38
mecillinam MEC
trend · Escherichia coli lower UTI only
75 %
74 %
n = 38
ciprofloxacin CIP
trend · Escherichia coli
75 %
76 %
n = 38
trimethoprim TMP
trend · Escherichia coli lower UTI only
71 %
66 %
n = 38
70 %
55 %
n = 38
48 %
45 %
n = 38
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
13 %
n = 38
4 %
5 %
n = 38
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
5 %
n = 38

Most likely organisms for this profile

Escherichia coli
56 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
9 %
Proteus mirabilis
6 %
Pseudomonas aeruginosa
5 %
Staphylococcus saprophyticus
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.